Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2024 Oct 17

PMID 39418072

Authors

Ganfei Xu

Juan Yu

Jiacheng Lyu

Mengna Zhan

Jie Xu

Minjing Huang

Rui Zhao

Yan Li

Jiajun Zhu

Jinwen Feng

Subei Tan

Peng Ran

Zhenghua Su

XinHua Liu

Jianyuan Zhao

Hongwei Zhang

Chen Xu

Jun Chang

Yingyong Hou

Chen Ding

Affiliations

Soon will be listed here.

Abstract

Multi-omics studies of breast ductal carcinoma (BRDC) have advanced the understanding of the disease's biology and accelerated targeted therapies. However, the temporal order of a series of biological events in the progression of BRDC is still poorly understood. A comprehensive proteogenomic analysis of 224 samples from 168 patients with malignant and benign breast diseases is carried out. Proteogenomic analysis reveals the characteristics of linear multi-step progression of BRDC, such as tumor protein P53 (TP53) mutation-associated estrogen receptor 1 (ESR1) overexpression is involved in the transition from ductal hyperplasia (DH) to ductal carcinoma in situ (DCIS). 6q21 amplification-associated nuclear receptor subfamily 3 group C member 1 (NR3C1) overexpression helps DCIS_Pure (pure DCIS, no histologic evidence of invasion) cells avoid immune destruction. The T-cell lymphoma invasion and metastasis 1, androgen receptor, and aldo-keto reductase family 1 member C1 (TIAM1-AR-AKR1C1) axis promotes cell invasion and migration in DCIS_adjIDC (DCIS regions of invasive cancers). In addition, AKR1C1 is identified as a potential therapeutic target and demonstrated the inhibitory effect of aspirin and dydrogesterone as its inhibitors on tumor cells. The integrative multi-omics analysis helps to understand the progression of BRDC and provides an opportunity to treat BRDC in different stages.

Citing Articles

Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets.

Xu G, Yu J, Lyu J, Zhan M, Xu J, Huang M Adv Sci (Weinh). 2024; 11(46):e2401041.

PMID: 39418072 PMC: 11633542. DOI: 10.1002/advs.202401041.

References

Omoto Y, Iwase H . Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci. 2015; 106(4):337-43. PMC: 4409875. DOI: 10.1111/cas.12613. View

Buccitelli C, Selbach M . mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet. 2020; 21(10):630-644. DOI: 10.1038/s41576-020-0258-4. View

Lam K, Leon A, Hui W, Lee S, Batruch I, Faust K . Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity. Nat Commun. 2022; 13(1):116. PMC: 8748638. DOI: 10.1038/s41467-021-27667-w. View

Li Z, Wei H, Li S, Wu P, Mao X . The Role of Progesterone Receptors in Breast Cancer. Drug Des Devel Ther. 2022; 16:305-314. PMC: 8801368. DOI: 10.2147/DDDT.S336643. View

Luo J, Yang H, Song B . Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2019; 21(4):225-245. DOI: 10.1038/s41580-019-0190-7. View

Li Y, Kong X, Xuan L, Wang Z, Huang Y . Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment. J Cell Mol Med. 2021; 25(22):10327-10348. PMC: 8581311. DOI: 10.1111/jcmm.16946. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Pareja F, Brown D, Lee J, Da Cruz Paula A, Selenica P, Bi R . Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma to Invasive Ductal Carcinoma. Clin Cancer Res. 2020; 26(14):3682-3693. PMC: 7367727. DOI: 10.1158/1078-0432.CCR-19-2563. View

Song Q, Yang Y, Jiang D, Qin Z, Xu C, Wang H . Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues. Nat Commun. 2022; 13(1):4167. PMC: 9293992. DOI: 10.1038/s41467-022-31719-0. View

10.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

11.

Hu C, Qiao W, Li X, Ning Z, Liu J, Dalangood S . Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8T cells. Cell Metab. 2024; 36(5):1168. DOI: 10.1016/j.cmet.2024.03.013. View

12.

Long J, Li X, Zhang F . Targeting metabolism in breast cancer: How far we can go?. World J Clin Oncol. 2016; 7(1):122-30. PMC: 4734934. DOI: 10.5306/wjco.v7.i1.122. View

13.

Gundisch S, Hauck S, Sarioglu H, Schott C, Viertler C, Kap M . Variability of protein and phosphoprotein levels in clinical tissue specimens during the preanalytical phase. J Proteome Res. 2012; 11(12):5748-62. DOI: 10.1021/pr300560y. View

14.

Allred D, Clark G, Molina R, Tandon A, Schnitt S, Gilchrist K . Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992; 23(9):974-9. DOI: 10.1016/0046-8177(92)90257-4. View

15.

Farrell A, Slatcher R, Tobin E, Imami L, Wildman D, Luca F . Socioeconomic status, family negative emotional climate, and anti-inflammatory gene expression among youth with asthma. Psychoneuroendocrinology. 2018; 91:62-67. PMC: 5903571. DOI: 10.1016/j.psyneuen.2018.02.011. View

16.

Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M . Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab. 2001; 86(3):1072-7. DOI: 10.1210/jcem.86.3.7283. View

17.

Jahan N, Jones C, Layeequr Rahman R . Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review. Mol Cell Endocrinol. 2021; 531:111324. DOI: 10.1016/j.mce.2021.111324. View

18.

Smetherman D . Screening, imaging, and image-guided biopsy techniques for breast cancer. Surg Clin North Am. 2013; 93(2):309-27. DOI: 10.1016/j.suc.2013.01.004. View

19.

Song Z, Liu Y, Cheng G, Chang L, Yu Z, Chen M . Distinct mutational backgrounds and clonal architectures implicated prognostic discrepancies in small-cell carcinomas of the esophagus and lung. Cell Death Dis. 2021; 12(5):472. PMC: 8115141. DOI: 10.1038/s41419-021-03754-0. View

20.

Shi Y, Wang G, Lau H, Yu J . Metagenomic Sequencing for Microbial DNA in Human Samples: Emerging Technological Advances. Int J Mol Sci. 2022; 23(4). PMC: 8877284. DOI: 10.3390/ijms23042181. View